Good afternoon, and thank you for joining us for this presentation of Safeguard Scientifics' first quarter 2023 financial results. Joining me on today's call and webcast are Eric Salzman, Safeguard's Chief Executive Officer, and Mark Herndon, Safeguard's Chief Financial Officer. Following our prepared remarks, we'll open up the call to your questions. As always, today's presentation includes forward-looking statements. Reliance on forward-looking statements involve certain risks and uncertainties, including but not limited to the uncertainty of the outcomes of corporate strategic transactions, if any, the uncertainty of the future performance of our companies, our ability to make good decisions about the monetization of our companies, the ongoing support of our companies, our inability to entirely control our companies, fluctuations in the market prices if any of our companies are publicly traded, and the effect of regulatory and economic conditions generally, and other uncertainties described in our filings with the SEC. Many of these factors are beyond our ability to predict or control. As a result of these and other factors, our past financial performance should not be relied on as an indication of future performance. During the course of today's call, words such as expect, anticipate, believe, and intend will be in our discussion of goals or events in the future. Management cannot provide any assurance that future results will be as described in our forward-looking statements. We encourage you to read Safeguard's filings with the SEC, including our Form 10-Q, which describe in detail the risks and uncertainties associated with managing our business. The company does not assume any obligation to update any forward-looking statements made today. With that, I would now like to introduce Eric. Thanks, Matt. Thanks for joining us this afternoon for our Q1 2023 earnings call. The macro challenges we highlighted on our last two earnings calls relating to a more difficult capital raising and M&A environment continue to impact many of our companies. Given that, we thought it would be helpful to categorize the portfolio into two different buckets. Bucket one contains our four companies that are funded, growing, and executing on their business plans, albeit in a more difficult environment. Bucket two includes three companies that are facing near-term leverage and liquidity issues which could adversely impact the values that are recoverable to Safeguard. One company sits between these two categories, and while it will require additional funding and operational adjustments, it is not facing the same near-term challenges as the three companies in bucket two. Bucket one includes Clutch, Moxe, meQuilibrium, and Prognos. We expect these four companies to continue to make progress, and our plan is to exit in the ordinary course over the next two years. Those exits are expected to represent the vast majority of proceeds to Safeguard. The three companies in bucket two are facing critical challenges stemming from high debt loads, elevated burn rates, and/or limited M&A interest. These challenges have become more difficult over the past two quarters as the financing and M&A environment has weakened. While the operating performance of bucket two companies is mixed, the main factors creating their issues are leverage, liquidity runway, and burn rates. As we've highlighted on last quarter's call, this profile of company is extremely difficult to finance or sell in the current environment. For each of our bucket two companies, we are actively working with our co-investors and senior lenders to find a path to address leverage and liquidity challenges with the goal of preserving our ownership interests and achieving recovery value. We continue to explore all types of approaches to extract value from these positions. There are no assurances that we will be able to achieve this goal for bucket two companies, and we have reduced our expectations of exit proceeds, recognizing that the proceeds to Safeguard could be de minimis. Note that we expect the outcome to these situations to be known over the next four months, and we will update investors accordingly. As described in our press release, we deployed $3 million in a financing round for Prognos, which closed in April. The financing positions the company well to execute on its business model, we were joined by both new investors as well as existing ones who see the attractive business opportunity to use real-world data to drive better healthcare outcomes. Prognos platform is used by over 70 life science customers to accelerate the development of new drugs, improve the safety and efficacy of existing drugs, and identify new patient populations that may benefit from specific treatments. This capital should fund the company to cash flow breakeven, further details about this financing will be released by Prognos in the near future. Let me now address a question we received from several investors regarding Safeguard's cash balances and stock buyback plan. We had nearly $19 million in cash at the end of the first quarter, almost $16 million after the Prognos deployment. We have estimated our follow-on deployments for the remainder of the year at $0-$1.5 million, and our OpEx is stable at its current level. This means we will likely have excess cash beyond what we expect to need to operate and run off the portfolio. As disclosed in our press release, we completed our $3 million stock buyback plan this past quarter. We approved the plan in March 2022, prior to the start of the Houlihan Lokey process because we had an open trading window. Since that time, the trading window for us has been closed due to the Houlihan Lokey discussions, so we have been unable to expand the existing $3 million buyback plan or establish a new buyback plan. As it relates to the Houlihan Lokey timeline, as we indicated on the last earnings call, we expect to announce a decision on the process between June and December of this year. At the conclusion of that process, we will reevaluate ways to return excess cash to our shareholders through buybacks or dividends. In the meantime, we will use our cash resources sparingly and judiciously. I'll now provide an update on portfolio M&A and exits. We have two active M&A situations in the portfolio. One of our companies launched a sale process earlier in the year and has received several non-binding initial indications of interest. Those interested parties are currently performing further diligence and have been asked to submit letters of intent in the next few weeks. While it is still early to handicap the odds of a deal happening, if one were to move forward, it could close in Q3 or Q4. Another M&A process we mentioned on last quarter's call involved one of our companies that has been in discussions for a stock-for-stock merger. The parties continue to work on this deal, but the timing has extended from the original timeline, and terms are likely to be modified. We are hopeful we can agree on terms acceptable to both sides, but there is no assurance a final deal can be agreed to. Note that neither of these companies are in bucket two. There is also ongoing M&A and capital raise activity at some of the bucket two companies as part of their restructuring efforts. Let me talk about our strategic process. On our strategic process, we are in exclusive discussions with one counterparty. While we cannot go into too much detail at this time, the goal of the transaction is to enable the vast majority of exit proceeds from the portfolio to flow to our current shareholders to reduce our operating expenses and to gain scale. We are in their structuring and diligence phase, so there can be no assurance that a deal will be reached. This transaction, should it move forward, would be subject to Safeguard shareholder approval. I'll now provide some company highlights. The Q1 highlights that we discussed today relate to our bucket one companies. Note that these are not exhaustive and do not reflect all the risks inherent in these venture stage companies. Moxe increased the number of live connections to its healthcare providers by 49% in Q1, 2023. Its Q1 revenues per healthcare provider site is up 142% year-on-year, and the company was issued its first patent. meQuilibrium exceeded planned revenues and EBITDA targets for Q1. Its Q1 2023 revenues were up 28% year-on-year. Its EBITDA loss was reduced by 70% year-on-year, and operating cash flow improved by 51%. For Prognos, the biggest highlight is the funding round that we mentioned earlier. On the business side, 100% of the business has pivoted to the marketplace model. The company is executing to plan and is on track to nearly triple its bookings for 2023. Clutch's Q1 total revenues were up 54% year-on-year, and reoccurring revenues were up 30% year-on-year. In Q1 2023, the company added 9 new customers and onboarded 5 new customers. Let me comment on public comps in trading multiples. We regularly track the revenue multiples and revenue growth of our publicly traded peer companies to help investors triangulate on what some of our companies could be worth using these same metrics. Given the bucketing of the portfolio that we described at the outset, we believe that these trading data points are relevant for the five companies which are not in bucket two. For the bucket two companies, given their situations, traditional valuation metrics do not apply. As of April 25th, our tech-enabled healthcare peers were trading at 3.6x 2023 consensus revenue and 3.5x 2024 consensus revenue. 2023 consensus revenue growth for these tech-enabled healthcare peers was 11%, with 12% consensus revenue growth for 2024. As of April 25th, the marketing technology peers, which is relevant for Clutch, were trading at 2.8x 2023 consensus revenues and 2.6x 2024 consensus revenues. 2023 consensus revenue growth for these marketing technology peers was 10% and 13% consensus revenue growth for 2024. Note that this data has not changed much from our Q4 2022 call. At this time, I will hand it over to our CFO, Mark Herndon. Thanks, Eric. Safeguard's net loss for the quarter ending March thirty-first, 2023 was $3.5 million or $0.22 per share, as compared to the net loss for 2022's net first quarter of $6.7 million or $0.40 per share. As we disclosed last quarter, we completed the remaining purchases under the $3 million 2022 share repurchase plan during the quarter by acquiring about 25,000 shares earlier in January. In total, the 2022 repurchase program repurchased 736,577 shares at an average price of $4.09 per share. We ended the quarter with $18.8 million of cash equivalents, restricted cash, and marketable securities. We continue to have no debt obligations. Our general and administrative expenses were $1.2 million for the first quarter of 2023 and 2022 on a rounded basis. Year-over-year decrease was 4%. Similarly, corporate expenses for the quarter, which represent general and administrative expenses excluding stock-based compensation, severance expenses, and non-recurring and other items were $0.8 million on a rounded basis for each of the first quarters of 2023 and 2022. The year-over-year decline was 6.4% there. We continue to expect the quarterly level of corporate expenses have stabilized at this approximate point. With respect to our ownership interests, we have an aggregate carrying value at March 31st, 2023 of $12 million as compared to $15.4 million at December 31st, 2022. This quarter's activity was limited to the application of equity method accounting, which generally reduces our carrying value based on our share of the losses of our companies. Our reported share of the losses of our equity method ownership interest for the three months ended March 31st, 2023 was $2.6 million as compared to $3.9 million for the comparable period in 2022. This decrease is largely the result of several companies reaching zero carrying value. At that point, we generally cease recording losses from that entity. I would also like to remind everyone that we report our share of the losses from the equity method companies on a one-quarter lag. This quarter's share losses reflect the fourth quarter of 2022. With respect to our ownership interest, the third party debt of this group of eight companies was approximately $226 million versus $209 million at the 2022 year-end. This increase is primarily related to one of our companies accessing a line of credit that had previously been established at Silicon Valley Bank. Cash at the same group of eight companies has decreased to about $59 million from $71 million last quarter. This decrease primarily related to the quarterly burn at a couple companies. In terms of revenue performance, we reported an 8.9% increase of this group of eight companies for the trailing 12 month period ended December 31st, 2022 due to the one quarter lag. We continue to see our fastest growth from Moxe and meQuilibrium. Now it's time for us to turn it over to the Q&A segment of the call. I'll ask the operator to open up the lines for questions. Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions. First question comes from Matt Burmeister with Private Investor. Please go ahead. Hi. The June to December decision timeline, what was that in regards to again? The June to December timeline is an announcement on the Houlihan Lokey strategic process that we've been working on. Okay. Is that separate from this recent update about the single counterparty in this advanced discussions? Is that separate from Houlihan Lokey process, or are they one and the same? They are one and the same. The Houlihan Lokey process has resulted in us, as we described, entering into an exclusivity agreement where we're having discussions with one counterparty. The outcome of those discussions and the overall process with Houlihan Lokey will be announced sometime between June and December of this year. I do believe we've got a web question, Matt. You wanna go ahead and ask it? Sure. The question from the web is, for the strategic process, you mentioned gaining scale as a possible beneficial outcome of the current transaction being discussed. Can you explain why that would be a goal for the company? Sure. Gaining scale could be a goal or an advantage for the company and its shareholders for a couple of reasons. First of all, greater scale could generate greater trading volume for the stock as our trading volume has declined dramatically over the past year. That's one benefit that could be gained through scale. The second is that scale would help amortize the operating expenses over a bigger base because as we've spoken about in the past, there's a fixed amount of operating expenses to manage the portfolio and to operate as a public company to a larger scale would help share those costs across a larger operation or base of assets. Okay. Our next question from the web. There was a recent announcement that MediaMath has put itself up for sale. Can we reasonably expect to receive anything, or should we expect not to get anything? We're really not at liberty to comment on their specific M&A process. I think for the purposes of our internal purposes, we're not ascribing much value to MediaMath. It is possible that a successful M&A outcome, if it were to happen, could result in something, but we're not factoring it in internally as anything more than de minimis. Next question from the web: What are the four companies in bucket one again? Sure. Those companies are meQuilibrium, Moxe, Prognos and Clutch. Clutch. Yep. That was our last question from the web. Okay, we do have a follow-up question from Matt Burmeister. Matt, your line is live. Yeah. The single counterparty, it says in the announcement that they're in advanced discussions. It seems like it's a little farther along based on that announcement. How come such a wide time window from June to December? That seems like a pretty long time window. The discussions are underway, and working as expeditiously as possible to get to a transaction, if there is one that is, that is doable, and that we think would be superior for our shareholders than just a runoff plan. The transaction would also, as I mentioned, require Safeguard shareholder approval. There are a number of things involved in both, on the diligence side with the counterparty, on the structuring side, addressing tax issues, and then determining what the implications are for us to go and, you know, get shareholder approval. That's the reason for the timeframe from between May now. From June to December is kind of between one month, one month and, call it, six months. I'm a little confused how you guys are talking about we're gonna get achieved scale from this transaction. I'm not, I'm not following what that plan looks like. Yeah. Well, we haven't given too much detail, as you can understand, given that we are under an exclusivity agreement and are doing work. We just wanted to highlight some of the goals and objectives that we would be looking to achieve from a transaction. If we get to a point where a deal has been signed, we of course will share with the investors and our shareholders, all the benefits and advantages of that transaction, as well as any risks that are associated with that transaction. All right. Best of luck. Eric, we have one more question from the web. It asks: Can you please elaborate about the company that is not in either bucket? The company that is not in either bucket. I think what we. Again, a lot of these companies are obviously quite fluid, as you've seen over the last two or three quarters. The one company that is neither in bucket one or bucket two, we're working to get it into bucket one, let's put it that way. But that is a process that's underway. The company, as I mentioned, will need additional capital. It will also need some operational changes and some cost cuts. That is a project that we're working on together with the other investors, the management team, and the lender to try to achieve an outcome for that company that would move it into bucket one. Next question from the web. Could you talk through how you were evaluating the Bright Health from the end of 2021 when the lockup ended until the time that you sold it? Yeah. I can, I can make some comments, and Mark may have something also to add to it. When the lockup ended, the stock of Bright Health was $3 and change. It was obviously down from the $18 IPO price with a top-tier investor group, management team, and a interesting business model that would use technology to help lower the cost and improve the efficiency in the insurance market, both for Medicare Advantage, Obamacare and other ACA and other. The company had significant opportunity, and we followed the company each quarter. As we may have called out at some point, the company had a cap plea to address that capital need. We were looking at that as other catalysts for the stock to go higher. We evaluated the performance each quarter and, like anything from the investing standpoint, you can't look in the rearview mirror. At the point in time that we decided to sell our position, we had concluded that the company and the management team were not going to deliver on any of the requirements or the objectives that we were looking for to achieve our target exit price. At that time, we looked to to exit the position in the market. I don't know, Mark, if there's anything more you'd like to add to that. Yeah. I was just gonna reiterate the vast majority. I think the percentage was something like 85% of the decline happened during the restricted phase. The other aspect of this is, you know, we didn't have immediate cash needs throughout the year, right? We weren't. You know, we had sufficient cash resources already throughout the year, we were able to make the investment decision as Eric laid out throughout the year. Okay. That was our last question from the web. Okay. Thank you all for joining us on the call today. Please contact us if you have any follow-up questions. Thanks very much. Have a nice evening.